Skip to content
ContentLora

    Tip: press / anywhere to search.

    technology

    Optogenetics

    Also known as optogenetic stimulation, channelrhodopsin method

    Optogenetics is a method that puts light-sensitive proteins, first found in microbes, into chosen nerve cells so researchers can switch them on or off with light in a living brain.[1] It earned Karl Deisseroth, Peter Hegemann and Georg Nagel the 2026 Nobel Prize in Physiology or Medicine. It is mainly a research tool, and its first clinical use is in trials to restore vision.[2][3]

    Editor reviewedStrict sourcingUpdated WikiNeuroscience and brain-computer interfaces, Health and medicine, Life sciences
    Key facts

    Optogenetics lets researchers turn specific nerve cells on or off with light in a living animal.[1] It drew wide attention in October 2026, when its developers won the Nobel Prize in Physiology or Medicine.[2] This page is the first step in a short course on the method, the scientist most associated with it, and its prospects in medicine. It is for information only and is not medical advice; talk to a clinician about any treatment.

    How it works

    The method starts with channelrhodopsin, a protein on the surface of the alga Chlamydomonas. When blue light hits it, a channel opens, charged ions flow into the cell and an electrical impulse follows. Any cell given the protein becomes light-sensitive.[4] Researchers deliver the gene for such a protein, called an opsin, to chosen nerve cells, then use light of different colours to switch them on or off.[1] Delivering genes this way is the same basic problem gene therapy faces; see how gene therapy delivery works.

    Before optogenetics, neuroscientists relied on electrical stimulation and drugs. Electrical stimulation also triggers neighbouring circuits and cannot precisely silence neurons. Drugs spread widely and cannot be switched off quickly.[5] The 2005 paper that started the field showed reliable control of neuron firing on a millisecond timescale.[6]

    History

    Hegemann and Nagel discovered channelrhodopsin, and Karl Deisseroth turned it into a switch for nerve cells.[7] Deisseroth’s group triggered nerve signals in rat neurons with blue light, published in 2005, and two years later made the method work in living mice.[8] The method got its name in 2006. In 2007 it was used to control whisker movements in mice through a thin optical fibre.[9] Uptake was slow at first. Deisseroth later wrote that 2005-2009 brought few publications and limited findings, followed by thousands of discoveries.[10]

    What it has revealed

    Optogenetics has been used to find circuits that govern pain, social behaviour, thirst, eating, reward and attention.[11] In 2012 a collaboration including Deisseroth reactivated the cells holding a fear memory in mice. The Nobel committee calls this the first demonstration of exactly which cells a specific memory needs.[12] The committee says the method has sharpened understanding of depression, anxiety, schizophrenia, Alzheimer’s disease and Parkinson’s disease.[13] Rodent studies have used it to switch depression-like symptoms on and off by controlling dopamine neurons.[14]

    Clinical use so far

    As of October 2026, optogenetics in people is limited to experiments. Clinical trials are trying to restore some sight to people blinded by retinitis pigmentosa, a disease that destroys the eye’s light-sensing cells.[3] In one published case, a blind patient was given a light-sensitive protein in the eye and wore special goggles, and could then find and touch objects.[15] Researchers also hope to make cochlear implants for hearing more precise.[16]

    In technical terms, the 2021 Nature Medicine report was the first reported case of partial functional recovery in a neurodegenerative disease after optogenetic therapy. The patient with retinitis pigmentosa received an intraocular adeno-associated viral vector encoding ChrimsonR, combined with goggles that project light pulses onto the retina.[15] It describes one patient, not a controlled trial.[15] Stanford describes eventual use with gene therapy, for example to restore function in paraplegia, as a possibility for the future.[17]

    For brain uses, including psychiatry, the evidence is still mostly from animals, such as the rodent depression studies.[14] Our analysis From optogenetics to psychiatry sets out the competing views, and the neurotech tracker follows brain-computer interfaces, a related clinical field.

    Neuroscience & BCI

    Karl Deisseroth

    Karl Deisseroth, Stanford psychiatrist and bioengineer, shares the 2026 Nobel Prize in medicine for optogenetics. His work, CLARITY and mental-health research.

    Developing in Health

    Go deeper

    Questions readers ask

    What is optogenetics in simple terms?

    It is a way to control chosen brain cells with light. Researchers give nerve cells the gene for a light-sensitive protein from algae, then shine light to switch those cells on or off.[1][4]

    Who invented optogenetics?

    The 2026 Nobel Prize credits Peter Hegemann and Georg Nagel with discovering channelrhodopsin in an alga and Karl Deisseroth with turning it into a light switch for nerve cells.[7]

    Is optogenetics used to treat people?

    Only experimentally. Clinical trials are trying to restore vision in people blinded by retinitis pigmentosa, and a 2021 report described partial vision recovery in one patient.[3][15]

    Why is it better than older methods?

    Electrical stimulation also activates neighbouring cells and cannot precisely silence neurons, and drugs spread widely and act slowly. Optogenetics targets defined cells and works on a millisecond timescale.[5][6]

    What has optogenetics revealed about the brain?

    Researchers have used it to identify circuits for pain, social behaviour, thirst, eating, reward and attention, and to pinpoint the cells holding a specific memory in mice.[11][12]

    Sources

    · 17 claims from 7 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Optogenetics uses light-sensitive proteins called opsins, originally found in microbes, inserted into chosen nerve cells so that light can switch those cells on or off in a living brain. confirmedas of 2026-10-05

    2. [2]

      On 5 October 2026 the Nobel Assembly at Karolinska Institutet awarded the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, Peter Hegemann and Georg Nagel "for their discoveries concerning light-gated ion channels and optogenetics". confirmedas of 2026-10-05

    3. [3]

      As of October 2026 the main clinical use of optogenetics is in trials to restore vision in people blinded by retinitis pigmentosa; in one person, a channelrhodopsin-like protein plus light-emitting glasses restored enough vision to locate and grasp objects. confirmedas of 2026-10-05

    4. [4]

      Channelrhodopsin is an algal surface protein that opens an ion channel when lit by blue light, letting charged ions flow in and create an electrical impulse; cells given the protein become light-sensitive. confirmedas of 2026-10-05

    5. [5]

      Before optogenetics, the main tools for studying brain circuits were electrical stimulation, which also activates neighbouring cells and cannot precisely inhibit neurons, and drugs, which diffuse widely and act slowly. confirmedas of 2026-10-05

    6. [6]

      The 2005 Nature Neuroscience paper by Boyden, Zhang, Bamberg, Nagel and Deisseroth reported reliable, millisecond-timescale control of neuronal spiking in mammalian neurons using channelrhodopsin-2. confirmedas of 2005-08-14

    7. [7]

      The Nobel committee credits Hegemann and Nagel with discovering channelrhodopsin, a protein from a single-celled alga, and Deisseroth with transforming it into a light-controlled switch for nerve cells. confirmedas of 2026-10-05

    8. [8]

      Deisseroth introduced the channelrhodopsin gene into rat nerve cells and triggered nerve signals with blue light, publishing in 2005; two years later he made the method work in the brains of living mice. confirmedas of 2026-10-05

    9. [9]

      The method was named optogenetics in 2006, and in 2007 Deisseroth's group controlled whisker movements in living mice by delivering light through a thin optical fibre. confirmedas of 2026-10-05

    10. [10]

      In a 2015 review Deisseroth wrote that optogenetics had few publications and limited findings in 2005-2009, followed by thousands of discoveries in the following years. confirmedas of 2015-09-01

    11. [11]

      Researchers using optogenetics have identified neural circuits governing pain, social behaviour, thirst, food consumption, reward and attention. confirmedas of 2026-10-05

    12. [12]

      In 2012 Deisseroth and collaborators reactivated the nerve cells holding a fear memory in mice, which the Nobel committee calls the first demonstration of exactly which cells are necessary for a specific memory. confirmedas of 2026-10-05

    13. [13]

      The Nobel committee says optogenetics has improved understanding of the distinguishing features of depression, anxiety, schizophrenia, Alzheimer's disease and Parkinson's disease. confirmedas of 2026-10-05

    14. [14]

      A 2013 Nature study from Deisseroth's lab found that inhibiting or exciting specific midbrain dopamine neurons in rodents immediately induced or relieved multiple depression-like symptoms caused by chronic stress. confirmedas of 2012-12-12

    15. [15]

      A 2021 Nature Medicine case report described the first partial functional recovery after optogenetic therapy in a neurodegenerative disease, in one blind patient with retinitis pigmentosa who received a viral vector encoding ChrimsonR and used engineered goggles. confirmedas of 2021-05-24

    16. [16]

      Researchers hope optogenetics could make cochlear implants for hearing loss more precise by activating the auditory nerve with light instead of electricity. confirmedas of 2026-10-05

    17. [17]

      Stanford says optogenetics may eventually be used in humans together with gene therapy, for example to restore function to people with paraplegia. reportedas of 2026-10-05· forecast

    Revision history (1)
    1. Page created.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Jan 11, 2027.

    Cite this page

    "Optogenetics." ContentLora, updated Oct 11, 2026. https://contentlora.com/wiki/optogenetics

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Connections
    Karl Deisseroth Developed by
    ☰ Contents